Pharmaceutical major Sun Pharmaceutical Industries on Thursday informed that its unit has received a tentative approval from the U.S. Food and Drug Administration to sell generic Uroxatral (Alfuzosin HCl) Extended Release tablets.

The company said in a communiqué that Alfuzosin HCL 10 mg tablets are therapeutically equivalent to Uroxatral Extended Release tablets from sanofi-aventis, and are used to treat benign prostatic hyperplasia, commonly known as enlarged prostate.

According to a report, Alfuzosin hydrochloride tablets have annual sales of approximately USD 180 million in the US.

The scrip of the company today closed at Rs 1289, marginally down compared to its previous close. The counter has made 52-week high and low of Rs 1558 and Rs 953 respectively.